$KOD: Kodiak's Left-for-Dead Eye Drug Just Passed Its Pivotal Trial, and the Stock Gapped 70% Before the Open
Kodiak's DAYBREAK Phase 3 hit on both drugs, with six-month dosing under the strictest retreatment rules yet used in wet AMD. Behind the 70% gap: a $126M cash pile, a near-certain raise, and the number the topline release left out.
Before Monday's opening bell, Kodiak Sciences (Nasdaq: KOD) released the trial result its entire $2 billion valuation was riding on, and it was a clean hit. In the pivotal Phase 3 DAYBREAK study in wet age-related macular degeneration, both of the company's drug candidates met their primary endpoints against aflibercept, the standard of care. By 7:45 a.m. Eastern, the stock was quoted around $55 in premarket trading, up roughly 70% from Friday's close of $32.35, pricing the company north of $3 billion before the market even opened.
To understand why the reaction is this violent, you need the backstory, because Zenkuda, the drug that just succeeded, is a molecule the market had already buried once. In July 2023, this same compound, then known only as tarcocimab tedromer, failed two pivotal Phase 3 studies in diabetic macular edema. In the GLIMMER study, patients on tarcocimab gained an average of 7.4 eye-chart letters against 12.2 letters for aflibercept, and the culprit was an unexpected safety signal: cataract adverse events in 19% of tarcocimab patients versus 9% on the comparator across the pooled studies. Kodiak announced it was discontinuing the program. The stock, which had traded above $170 at its early-2021 peak on the promise of this exact franchise, was cut in half on the news and spent the following year drifting as a cash shell with a grudge. Its 52-week low is $10.94.
Then Kodiak did something biotech companies almost never do successfully: it brought the dead molecule back. The company reformulated tarcocimab into an enhanced 50 mg/mL presentation, blending conjugated and unconjugated antibody to balance immediacy and durability, submitted a new pivotal protocol to the FDA in early 2024, and enrolled DAYBREAK. Today's readout is the verdict on that gamble.
The topline numbers explain the premarket move. Zenkuda achieved non-inferiority in vision gains versus aflibercept at one year with a p-value of 0.0007. More commercially important: 54% of Zenkuda patients reached a six-month dosing interval at year one, and they did it under what Kodiak calls strict treat-to-dryness retreatment criteria, meaning any detectable retinal fluid on imaging triggered retreatment. That is a harder test than the label-based interval extensions competitors have used, and it mirrors how retina specialists actually practice. The second drug in the study, tabirafusp tedromer (KSI-501), a bispecific targeting both VEGF and IL-6, also met its vision endpoint (p=0.0036) and hit its key anatomical secondary endpoint with a p-value below 0.0001.
And the detail that matters most given the history: the safety signal that killed this molecule in 2023 has inverted. Intraocular inflammation on Zenkuda was 0%, and cataract adverse events came in at 0.5%, below the 0.9% observed in the aflibercept arm. The reformulation appears to have solved the exact problem that destroyed the first version.
Kodiak says it will now submit a single biologics license application for Zenkuda in the fourth quarter of 2026 covering three indications at once: wet AMD, diabetic retinopathy, and macular edema following retinal vein occlusion, built on what the company describes as five positive Phase 3 studies. The target is the anti-VEGF retina market, which Kodiak sizes at roughly $15 billion, where Regeneron's Eylea HD did $1.6 billion in US sales in 2025 (up 36%) and Roche's Vabysmo did CHF 4.1 billion globally (up 12%).
Get the next briefing free in your inbox: Join AlphaBriefing
So the science worked. The question the premarket price is now asking is different: what is a one-product-family retina company worth on the morning its lead asset graduates, when it has $126 million in the bank, a burn rate that consumes that in under a year, a financing it almost certainly has to do into this strength, and two entrenched competitors whose answer to durability is already on the market? The topline release also leaves out the one number retina specialists will ask for first. What Kodiak disclosed, what it held back, and how the next twelve months of catalysts stack against the dilution math is where this stops being a headline and starts being a setup.
The rest of this briefing is for paid members: the real share-count and dilution math behind the $3 billion premarket valuation, the balance-sheet clock and why a capital raise is the near-term event to plan around, the number missing from this morning's topline release, the full catalyst calendar through mid-2027, and the scenario-by-scenario price zones.
AlphaBriefing Paid gets you every investment thesis, scenario framework, and catalyst brief we publish, the analysis private intel clients pay four figures for, at a fraction of that.